Home / Learn / Immunotherapy / View All IO Resources

View All IO Resources

Here is a comprehensive list of all of our immuno-oncology resources. Enter your search terms in the box below to filter your results.

Displaying results 1 - 20 of 57

1 2 3 Next
March 3, 2021
Washington Hilton 1919 Connecticutt Ave. NW Washington, D.C. 20009 202-483-3000
Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the immunotherapy care process.
Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.
Learn about the mental health implications of treatment with cancer immunotherapy, and how cancer care providers can better integrate mental health awareness into the IO care continuum.
April 16, 2020
Tammy Turner, Executive Director, Community Cancer Center, and Nancy Laney, President, Laney IT Consulting, discuss the most important strategies for planning, building, and implementing a telehealth program. (April 16, 2020)
April 9, 2020
Teri Bedard, BA, RT(R)(T), CPC, Director, Client Services, Revenue Cycle Coding Strategies LLC discusses CMS’ changes to telehealth coding and billing in response to the COVID-19 public health emergency, includes Q&A. (April 9, 2020)
Discover the results of the 2019 Trending Now in Cancer Care Survey—what tops the list of challenges, what areas are trending towards growth, and how cancer programs are evolving to meet the demands of 21st-century cancer care delivery.
How do interest specialists outside the field of oncology in participating in an inter-specialty immune-related adverse events (irAEs) tumor board? Cleveland Clinic discovered the key is to recruit physician champions who are not oncologists.
Johns Hopkins was one of the first institutions to use immunotherapies to treat intractable cancers. Because IO therapies can affect any of the body's organ systems, there was early recognition of the value of having a multidisciplinary team of organ specialists who could bring their expertise to the treatment of patients experiencing immune-related adverse events (irAEs).
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.
ACCC’s Immuno-Oncology Institute has developed the Survivorship Care Plans for Patients Receiving Immunotherapy as a resource for cancer programs and practices. and describes processes for developing survivorship care plans (SCPs) for patients treated with immunotherapy, effective practices in SCP design, and considerations for SCP delivery for this patient population.
December 9, 2019
With an increasing demand for cancer care services in a growing population, telemedicine and technology are becoming a vital component of delivering high-quality, value-based cancer care. Innovative e-health platforms and virtual navigation services can improve patient care by mitigating barriers for patients who are appropriate for cancer immunotherapy treatment, yet implementation of, and reimbursement …
Learn why a trip to the emergency department is different for patients who receive immunotherapy for cancer, what information helps ED clinicians, and what busy emergency department providers need to know about immune-related adverse events.
Many organizations have published formal recommendations, or workup guidelines, for managing irAEs, including ASCO, ESMO, NCCN, and SITC.The following can be used as a directory for the current irAE workup guidelines.
Download a summary of what occured during the ACCC 45th Annual Meeting & Cancer Center Business Summit in March 2019, where a Deep Dive Workshop on Real-World Integration of Immuno-Oncology brought together an expert panel for a focused discussion on step therapy in the context of immunotherapeutics. Panelists explored step therapy from the perspective of different members of the care team, including …
Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.
Our busy community practice first began treating patients with immunotherapy through participating in the original ipilimumab clinical trials. We quickly realized that this new treatment paradigm would require us to create and implement an effective screening and management tool for our immunooncology (IO) patient population.

Displaying results 1 - 20 of 57

1 2 3 Next